Ontario – Toronto GTA – Mississauga
Corporation
www.astrazeneca.ca
Ontario
Toronto GTA
Mississauga
Corporation
active
AstraZeneca Canada Inc. is a wholly owned indirect subsidiary of AstraZeneca PLC with global headquarters in London, England. Shares of AstraZeneca PLC are traded publicly on the New York Stock Exchange, London Stock Exchange and Stockholm Stock Exchange under the symbol 'AZN'.
AstraZeneca is one of Canada€™s and the world€™s leading pharmaceutical companies, with a product portfolio spanning six major therapeutic areas: cardiovascular, gastrointestinal, oncology, respiratory, neurological and infection. Some of AstraZeneca€™s key products include Arimidex®, Atacand®, Crestor®, Nexium®, Seroquel® and Symbicort®.
AstraZeneca employs more than 64,000 people in 150 countries. The company employs more than 1,400 people across Canada, who work to discover, develop, package, distribute and market medicines to improve the lives of Canadians. AstraZeneca۪s Canadian headquarters are located in Mississauga, Ontario, and the company also has a state-of-the-art research facility in Montr̩al.
Research and Development
Research and development (R - D) is the foundation of AstraZeneca€™s success in bringing new products to market. Highly-skilled Canadian scientists are part of a global team that works toward the discovery and design of novel and effective pharmaceutical agents and technologies. Worldwide, the company spends approximately US$3.5 billion annually. In Canada, AstraZeneca invests more than $100 million annually - approximately $2 million each week - in R - D, placing the company among the top 30 contributors to R - D in Canada.
At AstraZeneca Research - Development Montréal (AZRDM), more than 125 highly skilled scientists are focused on finding new and innovative therapeutic solutions to treat acute and chronic pain. Opened in 1997, AZRDM has already filed patents on new discoveries that AstraZeneca hopes will improve the lives, not only of Canadians, but also of people around the world.
AstraZeneca also pursues strategic research collaborations with external companies and academic institutions to support and enhance its drug discovery and development programs.
Community Investment
As a part of AstraZeneca€™s commitment to improving the health and quality of life of Canadians, the company is dedicated to supporting a wide range of charitable, educational and environmental initiatives across the country. As an Imagine Canada Company, AstraZeneca is committed to donating a minimum of one per cent of pre-tax profits to Canadian community organizations and encouraging employee volunteering.
Country of Ownership: Canada
Year Established: 1999
Exporting: Yes
Primary Industry (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Primary Business Activity: Manufacturer / Processor / Producer
Total Sales ($CDN): $50,000,000 +
Export Sales ($CDN): $1,000,000 to $4,999,999
Number of Employees: 1500
Products:
Crestor® (rosuvastatin calcium), Atacand® (candesartan cilexetil), Arimidex® (anastrozole), Seroquel® (quetiapine fumarate), Symbicort® (budesonide and formoterol), Nexium® (esomeprazole magnesium), Merrem® (meropenem)
Charnetsky William
Cloutier Michael
Fleming Michelle
Mastrangelo Carlo
Relations Customer
No associations
LandOfFree
AstraZeneca Canada Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with AstraZeneca Canada Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and AstraZeneca Canada Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-47843